Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
13.26
+0.29 (2.24%)
Jul 30, 2026, 2:48 PM EDT - Market open

Lyell Immunopharma Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
3256541894938661,879
Market Cap Growth
59.57%246.59%-61.70%-43.11%-53.91%-
Enterprise Value
105.7448.81-130.813.35289.011,331
Last Close Price
13.2630.7812.8038.8069.40154.80
PS Ratio
10252.3118169.603093.823789.8610.23176.41
PB Ratio
1.112.640.490.751.042.02
P/TBV Ratio
0.912.120.440.741.031.13
EV/Sales Ratio
3409.5312466.90-2144.4225.803.41124.94
EV/EBITDA Ratio
--0.39---
EV/EBIT Ratio
--0.36---
EV/FCF Ratio
--0.80---
Debt / Equity Ratio
0.140.170.130.090.080.07
Net Debt / Equity Ratio
-0.78-0.83-0.83-0.75-0.69-0.59
Net Debt / EBITDA Ratio
0.870.800.942.163.412.73
Net Debt / FCF Ratio
1.601.361.962.942.982.86
Asset Turnover
0.000.000.000.000.080.01
Quick Ratio
6.885.006.8915.8217.2913.15
Current Ratio
7.235.287.0616.0717.5913.40
Return on Equity (ROE)
-94.43%-86.98%-66.10%-31.53%-20.77%-30.36%
Return on Assets (ROA)
-74.22%-64.85%-57.82%-29.27%-18.12%-21.10%
Return on Invested Capital (ROIC)
-315.57%-283.02%-234.01%-102.58%-47.51%-54.25%
Return on Capital Employed (ROCE)
-84.82%-74.04%-62.25%-30.57%-18.88%-22.15%
Buyback Yield / Dilution
-38.93%-30.74%-4.18%-1.58%-81.79%-925.18%
Total Shareholder Return
-38.93%-30.74%-4.18%-1.58%-81.79%-925.18%
SEC Filings: 10-K · 10-Q